significant reduction in number of spontaneous metastases and their incidence was observed. Again, the largest antimetastatic effect was observed for s.c. B16 melanoma with smaller effects observed for i.m. B16 melanoma or Lewis lung carcinoma. Experiments in which 4-OHA treatment was initiated after amputation of the primary tumour implanted in the tail confirmed that 4-OHA did have antitumour activity against disseminated tumour cells. The drug regimens studied to date produced significant delays in the appearance of spontaneous metastases in the lungs and significant increases in the life spans of the treated animals.
The discovery of melanocytotoxic activity of certain phenolic depigmenting agents due to their oxidation by tyrosinase, the 'clue' enzyme in cellular pigment formation, appeared to offer a therapeutic potential in the treatment of melanotic melanoma. Animal studies on experimental melanomas have given variable results as regards the therapeutic efficacy of these agents (Chavin & Schlesinger, 1967; Frenk & Ott 1971; Bleehen, 1973; Paslin, 1973) . Several other phenolic compounds with antioxidant properties were tested more recently for antitumour activity against murine melanomas (Demopoulos et al., 1976; Kanclerz, 1984) . The most active melanocytotoxic agent, to date, is an analog of tyrosine, 4-hydroxyanisole . Studies in vitro demonstrated its cytotoxicity against mammalian melanocytes (Riley et al., 1975; Breathnach et al., 1983) , including human melanoma cells (Bleehen, 1976; Kanclerz & Aubert, 1984; Meyskens, 1984) . Dewey et al. (1977) observed 'regression' of Harding-Passey melanoma in 46% of the animals treated with intratumoural application of 4-OHA. Webster et al. (1984) did not see any significant difference in weight of intramuscularly growing B16 melanoma after i.p. administration of 4-OHA, although a two day delay in appearance of tumours was noticed.
Clinical trials to evaluate the efficacy of 4-OHA therapy against human melanoma have been initiated. A small antitumour effect was found after i.v. or intratumoural application of the drug (Riley et al., 1982; Webster et al., 1984) and intra-arterial infusion of 4-OHA seemed to provoke regression of recurrent melanoma in some cases (Morgan et al., 1981; Morgan, 1984 Treatment regimen A Consisted of five injections of the drug at 50mgkg-I on days 3 to 7 after tumour transplantation as described previously (Kanclerz & Chapman, 1986 (Figure 2 ). It had little or no effect on the growth of primary i.m. B16 melanoma and had no effect on the growth of primary LLC (data not shown). In fact, pretreatment of animals with 4-OHA had a small, but significant, potentiating effect on growth of both tumours (schedule D, Figure 1) .
The average number of B16 melanoma pulmonary metastases per pair of lungs was significantly lower in 4-OHA treated animals for both growth sites (s.c. and i.m.) investigated (Table 1) . These effects were larger in the animals having s.c. tumour. The average number of LLC pulmonary metastases per animal was significantly lower in the mice treated with 4-OHA after tumour transplantation; however, 4-OHA pretreatment alone increased the number of metastases in the lungs.
Treatment regimen C
The number of metastases per pair of lungs was lower in all groups treated after tumour removal with the largest effect observed in the mice whose tumours had been amputated the earliest. Similarly, the wet weight of the lungs was lower in all experimental groups (Table II) . A slight increase in the number of pulmonary metastases and an increase of lung mass were observed in the animals treated with 4-OHA before surgery performed on day 23 (Table II) . The median survival time was longer in the groups of animals to which 4-OHA was administered after tumour removal (Figure 3) .
The experiments carried out on LLC revealed no differences in the number of pulmonary metastases nor in the lung weight between animals treated with 4-OHA before or after surgery and controls, although the treated animals survived longer than the non-treated ones (P>0.01).
Metastases of both tumours to lymph nodes were observed in all the groups of animals. Their frequency and their weights showed no differences between drug treated and control mice.
Discussion
The reported effects of 4-OHA on experimental melanomas are highly variable, showing no response in some systems and complete remission of murine tumours in others (Dewey et al., 1977; Webster et al., 1984) . Moreover, the effect of 4-OHA on naturally occurring metastases in animals has not been reported. In spite of these limited laboratory results the first clinical observations on a small number of treated patients suggest efficacy of 4-OHA therapy against secondary melanoma (Riley et al., 1982; Morgan et al., 1984) .
In our experiments we were able to measure a small, but significant, beneficial effect of 4-OHA therapy. Administration of 4-OHA in five i.p. injections from day 3 to 7 after tumour transplantation resulted in a relatively small, altnougn statistically signiticant, inhibition of the primary melanoma growth and had some inhibiting effect on spontaneous metastases formation. Effects of 4-OHA applied in a similar regimen to animals bearing Lewis lung carcinoma were transient and less evident than in the case of pigmented B16 melanoma (Kanclerz & Chapman, 1986) . Some increase of pulmonary LLC metastases was seen at different times after tumour challenge in experiments with i.m. growing tumours. Since 4-OHA is a relatively nontoxic substance an additional therapy was applied to determine if the effects of 4-OHA could be enhanced. This more aggressive therapy was accomplished by increasing the time and frequency of drug administration and hence augmenting the total dose given (Figure 1 ). Inhibition of s.c. melanoma growth was observed with this treatment (Figure 2 ) and a lower number of pulmonary metastases and their incidence was observed in these animals (Table I ). However, we were not able to observe any growth inhibition of melanoma growing i.m. An analysis of the tumour volumes revealed that tumours growing i.m. were more than 4 times larger than those growing s.c. at the time of treatment. It could be that the drug availability in the i.m. melanoma tissue was not adequate to produce any significant therapeutic effects in the faster growing tumours. In spite of the absence of any effect on the growth of i.m. melanomas, an inhibition of metastatic spread to ilanted B16 the lungs was observed (Table I) (Table II) .
The more pronounced effects of the applied 4-OHA treatment on B16 melanoma and its metastatic spread suggest specificity of the compound against pigmented tumour which is compatible with previously published results. Similarly, we observed longer survival times (up to 12 days) in animals treated after melanoma removal as compared to 3 days for mice having amputated LLC (Figure 3) . However, 4-OHA did not modify the spread of either tumour to the lymphatic system.
Our data suggest that 4-OHA has a moderate growth retarding effect on primary B16 melanoma. The finding that the antioxidant has some potential to suppress metastatic spread is of interest, particularly when considering that metastatic dissemination is a major cause of death due to cancer (Weiss, 1985) . 4-OHA effectiveness on B16 metastases formation appears most effective when the burden of disseminated disease is small.
